112 related articles for article (PubMed ID: 3901614)
21. Structural studies of a neutral polymeric fraction from the lipopolysaccharide of Serratia marcescens C.D.C. 1783-57 (O14:H9).
Brigden CJ; Wilkinson SG
Carbohydr Res; 1985 Dec; 145(1):81-7. PubMed ID: 3912043
[TBL] [Abstract][Full Text] [Related]
22. Specific and Nonspecific immunity to Serratia marcescens infection.
Simberkoff MS; Moldover NH; Rahal JJ
J Infect Dis; 1976 Oct; 134(4):348-53. PubMed ID: 789788
[TBL] [Abstract][Full Text] [Related]
23. Serotyping of Serratia marcescens: simplified tube O-agglutination test and comparison with other serological procedures.
Traub WH; Fukushima PI
Zentralbl Bakteriol Orig A; 1979 Sep; 244(4):474-93. PubMed ID: 396741
[TBL] [Abstract][Full Text] [Related]
24. Structure of the O-specific polysaccharide from the lipopolysaccharide of Serratia marcescens O8.
Oxley D; Wilkinson SG
Eur J Biochem; 1986 May; 156(3):597-601. PubMed ID: 2422032
[TBL] [Abstract][Full Text] [Related]
25. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen.
Hormaeche CE; Mastroeni P; Harrison JA; Demarco de Hormaeche R; Svenson S; Stocker BA
Vaccine; 1996 Mar; 14(4):251-9. PubMed ID: 8744548
[TBL] [Abstract][Full Text] [Related]
26. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.
Kreger AS; Lyerly DM; Hazlett LD; Berk RS
Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522
[TBL] [Abstract][Full Text] [Related]
27. Effect of active and passive immunizations with lipid A and salmonella minnesota Re 595 on gram-negative infections in mice.
Hodgin LA; Drews J
Infection; 1976; 4(2):5-10. PubMed ID: 789248
[TBL] [Abstract][Full Text] [Related]
28. Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides.
Cryz SJ; Meadow PM; Fürer E; Germanier R
Eur J Clin Microbiol; 1985 Apr; 4(2):180-5. PubMed ID: 3924605
[TBL] [Abstract][Full Text] [Related]
29. Potential use of shared antigens for immunization against gram-negative bacillary infections.
McCabe WR; DeMaria A; Johns M
Prog Clin Biol Res; 1980; 47():107-17. PubMed ID: 6163155
[TBL] [Abstract][Full Text] [Related]
30. Humoral antibody response of rabbits against experimental Serratia marcescens septicemia.
Traub WH; Bauer D
Zentralbl Bakteriol; 1990 Sep; 273(4):481-91. PubMed ID: 2248683
[TBL] [Abstract][Full Text] [Related]
31. Identification of capsular antigens in Serratia marcescens.
Aucken HM; Wilkinson SG; Pitt TL
J Clin Microbiol; 1997 Jan; 35(1):59-63. PubMed ID: 8968881
[TBL] [Abstract][Full Text] [Related]
32. Prior exposure to subimmunogenic amounts of some bacterial lipopolysaccharides induces specific immunological unresponsiveness.
Elkins KL; Stashak PW; Baker PJ
Infect Immun; 1987 Dec; 55(12):3085-92. PubMed ID: 3316031
[TBL] [Abstract][Full Text] [Related]
33. Opsonization requirements of Serratia marcescens.
Traub WH
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Nov; 253(2):204-24. PubMed ID: 6187137
[TBL] [Abstract][Full Text] [Related]
34. Isolation rate of non-hemagglutinating strains of Serratia marcescens from clinical specimens in a general hospital: comparison of serotypes O2 and O14.
Yanagawa Y; Marumo K; Nakamura Y; Shimamura T
J Infect Chemother; 2007 Jun; 13(3):151-6. PubMed ID: 17593501
[TBL] [Abstract][Full Text] [Related]
35. Serotyping of Serratia liquefaciens: H-antigens.
Traub WH
Zentralbl Bakteriol; 1991 Jun; 275(2):211-5. PubMed ID: 1718304
[TBL] [Abstract][Full Text] [Related]
36. Degradation of human fibronectin by metalloproteases of Serratia marcescens.
Traub WH; Bauer D
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):461-7. PubMed ID: 3901615
[TBL] [Abstract][Full Text] [Related]
37. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli.
Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT
Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122
[TBL] [Abstract][Full Text] [Related]
38. Immunophysical characterization of human isolates of Serratia marcescens.
Hamadeh RM; Mandrell RE; Griffiss JM
J Clin Microbiol; 1990 Jan; 28(1):20-6. PubMed ID: 2405011
[TBL] [Abstract][Full Text] [Related]
39. The role of O-antigen in susceptibility of Serratia marcescens to non-immune serum.
Palomar J; Montilla R; Fusté MC; Viñas M
Microbios; 1993; 76(308):189-96. PubMed ID: 8302200
[TBL] [Abstract][Full Text] [Related]
40. Structure of a neutral glycan from the lipopolysaccharides of reference strains for Serratia marcescens serogroups O2 and O3.
Oxley D; Wilkinson SG
FEMS Microbiol Lett; 1992 Dec; 78(2-3):209-12. PubMed ID: 1283379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
